PRE AND POST TREATMENT EFFECT OF IMATINIB AND ANTI-OXIDANT STATUS IN CHRONIC MYELOID LEUKEMIA PATIENTS

Main Article Content

Faiza Mehmood1
Uraiimov Elaman Toktobolotovich
Hafiz Muhammad Arsalan
Muhammad Shoaib Ramzan
Tilenov Azamat
Ali Waheed Goraya

Keywords

CML, Tyrosine kinase inhibitors, oxidative stress, Lipid Peroxidation, Imatinib

Abstract

Background: Chronic myeloid leukemia (CML) is being a disorder marked by excessive proliferation of bone marrow elements and especially blood cells (leucocytes). Structural characteristics in CML, loss of leucocytes function, chromosomal translocation between chromosome 9 and chromosome 22 forming Philadelphia (Ph) chromosome and enlarged spleen result in an imbalance between free radical production and antioxidant defences. CML is generally associated with old age, hypertension, Genetic mutation, environmental factors and oxidative stress. To determine the anti-oxidant status, micronutrients level in CML patients before and after treatment with Imatinib.


Methodology: Comparative Study. Fifty (pre-treatment imatinib) diagnosed patients of CML and same fifty (post treatment imatinib) CML individuals were taken in the study. Blood sample collected from Mayo Hospital Lahore. 5.0 ml blood samples were taken and subjected to centrifuge at 3000-4000 rpm for 10-15 minutes for the separation of serum. The levels of oxidative stress biomarkers (GSH, SOD, AGES, NO, AOPP, MDA), serum electrolytes and micronutrients were estimated.


Results: NO level in CML (post treatment imatinib) patients was elevated remarkably (0.418± 0.077) as compared to CML (pre-treatment imatinib) patients (0.188± 0.244) and statistically significant (p-value <0.00). MDA level was also increased in (post treatment imatinib) CML patients (0.451 ± 0.076) as compared to (pre-treatment imatinib) CML patients (0.257 ± 0.159) and statistically significant (p-value <0.00). The level of advanced oxidation protein product (AOPP) in CML (pre-treatment imatinib) patients was decreased (0.607 ± 0.0.136) as compared to CML (post treatment imatinib) patients (1.23 ± 0.271) and also statistically significant (p-value <0.00).


Conclusion:  The present study concluded that Strong association exists between Oxidative stress, Imatinib (TKI), Micronutrients and Serum electrolytes balance in CML patients. Pre- treatment imatinib patients of CML disease have increased Lipid per oxidation leads to elevated level of MDA remarkably where as Anti-oxidants decrease. Elevation in the Nitric oxide, Glutathione, superoxide dismutase and decrease level of vitamins are the cause for the progression of chronic myeloid leukemia CML disease.

Abstract 63 | Pdf Downloads 20

References

1. Abdollahi, M., Moridani, M. Y., Aruoma O. I., and Moustafalou, S. (2014). Oxid. Med. Cell. Longev.876834.
2. Abdullah, W. K., & Maha, F. A. (2022). Caspase 9 gene expression and caspase 9 protein in chronic myeloid leukemia in Iraq. Iraqi Journal of Agricultural Sciences, 53(5), 994-1002.
3. Abraham, A., Jain, H., Bhattacharyya, J., Biswajit, D., PK, J., Bhurani, D., Bala, S.C., Pramanik, S., Devadas, S., Kulkarni, U.P. and Sengar, M. (2022). Low dose dasatinib is not as active in a CML CP cohort enriched with intermediate/high-risk CML chronic phase: A phase IIb multi-center trial. Blood, 140(Supplement 1), pp.6789-6790.
4. Ahmed, A.A., Khaleel, K.J., Fadhel, A.A. and Al-Rubaii, B.A.L. (2022). Chronic Myeloid Leukemia: A retrospective study of clinical and pathological features. Bionatura, 7(3), 41.
5. Arsalan, H.M., Arif, A., Khan, M.K.A. (2023). Prospective biochemical analysis of chronic myeloid leukemia patients in response to tyrosine kinase inhibitors. Pakistan Journal of Zoology. 55(5): 2103-2111.
6. Achkar, W.A., Moassass, F., Youssef, N., Wafa, A. (2016). Correlation of p210 BCR–ABL transcript variants with clinical parameters and disease outcome in 45 chronic myeloid leukemia patients. JBUON. 21:444–9.
7. Ali, R., Ozkalemkas, F., Ozkocaman, V., Ozan, U., Kimya, Y., Nilgun, K., Gulten, T., Yakut, T., and Tunalı, A. (2016). Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML) Outcome of discontinuation of imatinib therapy after achieving a molecular remission. Leukemia Research. 29: 971–973.
8. Alkan, Ş. B., Artaç, M., Aksoy, F., Belviranlı, M. M., Gürbilek, M., Çizmecioğlu, H. A., & Rakıcıoğlu, N. (2023). Are dietary and serum advanced glycation end-products related to inflammation and oxidation biomarkers in breast cancer patients: a follow-up study. Supportive Care in Cancer, 31(6), 334.
9. Ashariati, A., Ugroseno, S. (2013). Profile of BCR–ABL transcript levels based on sokal prognostic score in chronic myeloid leukemia patients treated with imatinib. Acta Med Indones-Indones J Intern. 45:108–13.
10. Baccarani, M., Rost, G., and Soverini, S. (2019). Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type. Leukemia. 33: 2358–2364
11. Balatzenko, G., Vundinti, B.R., Margarita, G. (2011). Correlation between the type of BCR–ABL transcripts and blood cell counts in chronic myeloid leukemia – a possible influence of mdr1 gene expression. Hematol Rep. 3:5–9.
12. Berger, T., Shacham Abulafia, A., Shimony, S., Pasvolsky, O., Vaxman, I., Miron, Y., Feldman, S., Leader, A. and Raanani, P. (2022). Prevalence and Clinical Characteristics of Paraproteinemia Associated with Chronic Myeloid Leukemia. Acta Haematologica, 145(6), pp.619-626.
13. Bhatti, F.A., Ahmed, S., Ali, N. (2012). Clinical and hematological features of 335 patients of chronic myelogenous leukemia diagnosed at single centre in Northern Pakistan. Clin Med Insights Blood Disord. 5:16–24.
14. Bidikian, A., Jabbour, E., Issa, G.C., Short, N.J., Sasaki, K. and Kantarjian, H. (2023). Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor. American journal of hematology, 98(4): 639-644.
15. Bilajac, E., Mahmutović, L., Glamočlija, U., Osmanović, A., Hromić-Jahjefendić, A., Tambuwala, M.M. and Suljagić, M. (2022). Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines. Metabolites, 13(1), p.58.
16. Bourgeais, J., Ishac, N., and Medrzycki, M. (2017). Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leu‐ kemia cells by repressing antioxidant defenses. Oncotarget. 8(26):41876–41889.
17. Kakkar, P., Das, B., and Viswanathan, P.N. (1984). A modified spectrophotometer assay of superoxide dismutase. Indian J Biochem Bio.21: 130-132.
18. Ohkawa. H., Ohishi, N., Yagi, K. (1979). Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. J Anal Biochem, 95: 351-358.
19. Aebi, H. (1984). Catalase in Bergmeyer HU (eds.). Methods in Enzymatic Analysis, Academic Press. New York. pp. 276-286.
20. Moron, M.S., Depierre, J., Mannervik, B. (1979). Levels of glutathione, glutathione reductase and glutathione-S-transferase activities in rat lung and liver. BiochemBiophysActa, 582: 67-78.
21. Moshage, H., Kok, B., Huizenga, J.R., Jansen, P.L. (1995). Nitrite and nitrate determinations in plasma: a critical evaluation.Clin Chem. 41(6):892-896.
22. Roe, S., Keuther, N.S. (1943). Role of Vitamin C and micronutrients in Lungs and Liver.BiochemBiophysActa,26: 270-274.
23. Rosenberg, S.A., Packard, B.S., Aeborsold, P.M., Solomon, D., Topalian, S.L., Toy, S.T., Simon, P., Lotze, M.D., Yang, J.C., Seip, C.A. (1992). The use of tumor infiltrating and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N. Engl. J. Med.319:1676-1680.
24. Yeung, D.T., Shanmuganathan, N., Reynolds, J., Branford, S., Walia, M., Yong, A.S., Shortt, J., Burbury, K., Viiala, N., Cunningham, I. and Ross, D.M. (2022). Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML-Interim Results from ALLG CML13 Ascend-CML. Blood, 140(Supplement 1): 192-194.
25. Yuda, J., Doki, N., Matsuoka, H., Yokota, T., Tomita, A., Takahashi, N., Matsumura, I., Kubo, K., Goto, T., Kirito, K. and Maki, A. (2023). Asciminib vs bosutinib in CML patients pretreated with≥ 2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study. Cancer Medicine, 12(3): 2990-2998.
26. Zdenek, R., Belohlavkova, P., Cetkovsky, P., Faber, E., Klamova, H., Ludmila, M., Mayer, J. (2014). Comparison of glucose and lipid metabolism abnormality during nilotinib, imatinib and dasatinib therapy–results of Enigma 2 study.
27. Zhang, Z., Huang, X., Yan, Q., Lin, Y., Liu, E., Mi, Y., Liang, S., Wang, H., Xu, J. and Ru, K. (2022). The diagnosis of chronic myeloid leukemia with deep adversarial learning. The American Journal of Pathology, 192(7), pp.1083-1091.
28. Zhang, X. S., Gale, R. P., Zhang, M. J., Huang, X. J., & Jiang, Q. (2022). A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy. Leukemia, 36(5), 1336-1342.